Is Eli Lilly and Company (LLY) a good stock to buy?

Olyth's institutional analysis of LLY reveals an Altman Z-Score of 7.97 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($65.18B most recent), help investors decide if LLY fits their risk profile.

What is the current P/E ratio for LLY?

As of the latest trading session, Eli Lilly and Company (LLY) has a trailing P/E ratio of 40.32.

Who is the CEO of Eli Lilly and Company?

The current Chief Executive Officer of Eli Lilly and Company is David A. Ricks.

What was LLY's revenue for the last 5 years?

According to its latest income statements, Eli Lilly and Company reported annual revenues of $65.18B (2025), $45.04B (2024), $34.12B (2023), $28.54B (2022), $28.32B (2021) respectively.

Does LLY pay a dividend?

Eli Lilly and Company currently pays a dividend to its shareholders, with a trailing dividend yield of 0.67%.

How much debt and cash flow does LLY have?

In its latest reporting period, Eli Lilly and Company generated $8.97B in Free Cash Flow against a total debt load of $42.50B.

What is the Price-to-Book (P/B) ratio of Eli Lilly and Company?

The Price-to-Book (P/B) ratio for Eli Lilly and Company (LLY) is currently 31.36.

What is the Price-to-Sales (P/S) ratio of LLY?

Based on trailing twelve-month data, Eli Lilly and Company (LLY) trades at a Price-to-Sales (P/S) ratio of 13.43.

What is Eli Lilly and Company's Return on Equity (ROE)?

Eli Lilly and Company (LLY) has a Return on Equity (ROE) of 97.85%, representing its profitability relative to shareholder equity.

LLY

Eli Lilly and Company · Healthcare

926.65

0.95%(-8.93)

Prev. Close

932.00

0.58%(+5.35)

Pre-market

Last Updated: — ET

52W L: $623.7852W H: $1133.95

$928.87

CHG-47.90 (-4.90%)

H$1014.37

L$872.45

VOL37M

LLY (1h)

Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

47,000

IPO Date

1972-06-01

Beta

0.50

Websitewww.lilly.com↗

LLY

Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines

Lilly vs JPMorgan: Which Hits a $1 Trillion Market Cap First?

Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight

India's 'Mounjaro brides': weight-loss injections become part of pre-wedding preparation

Eli Lilly (LLY) Stock Sinks As Market Gains: Here's Why